Parents of Ontario girl with Rett syndrome fight for access to revolutionary gene therapy
The family of Lucia Vaccaro, who suffers from a rare neurogenetic disorder, is fighting for participation in a clinical trial of gene therapy by Taysha Gene Therapies after the protocol was changed at the FDA's request. The situation has drawn attention to the issue of access to experimental treatments and the ethics of clinical research.
"The door is open, but not for everyone": Why Lucia Vaccaro's story exposed the dirty secret of orphan clinical trials
Analytical review from an industry insider
May 25, 2026
\[The Gist]: What's really happening
Colleagues, forget the "parents fighting for access" narrative. The story of four-year-old Lucia Vaccaro from Ottawa is not just another touching segment for the evening news. It is the exposed nerve of the entire orphan gene therapy system, where the interests of pharma giants, FDA protocols, and human lives collide head-on. And now, in May 2026, that nerve is inflamed to the limit.
The essence of the conflict is cynically simple. Taysha Gene Therapies, a company with a market cap of nearly $2 billion, is advancing TSHA-102 — an intrathecal AAV9 therapy for Rett syndrome — along an accelerated path to approval. The protocol changed at the FDA's request, and Lucia, who is about to turn 5, ended up in a "dead zone": too old for the ASPIRE cohort (2–4 years) and too young for the main REVEAL cohort (6–22 years).
But the inside scoop that the public won't see is different: this is not an accident. It is a harsh, calculated trade-off between patient safety and the speed of bringing the drug to market. And in this trade-off, the Vaccaro family has become a bargaining chip.
\[Timeline and Context]
Why is this happening now, in May 2026, and not a year earlier? Because Taysha is on the home stretch before filing a BLA (Biologics License Application).
Let me break down the company's strategy. In Q4 2025, the key REVEAL trial launched with 15 patients aged 6 to 22. Simultaneously, in coordination with the FDA, a safety cohort called ASPIRE was initiated — just three children aged 2 to 4.
Why these three children? The magic of regulatory science. The FDA gave written consent that just three months of safety data from these three children would be sufficient to extrapolate the therapy's efficacy (data from REVEAL) to all patients aged 2 and older. This will allow for a broad drug label.
This is precisely where Lucia's "Achilles' heel" lies. Her parents were told in December that their daughter had been selected. But in January, Taysha announced a protocol change at the FDA's request, and Lucia (4 years and 11 months) fell out of ASPIRE, while REVEAL won't take her due to age. She is a "clinical orphan" in the literal sense.
Currently, according to Q1 2026 reporting, Taysha reported a net loss of $42 million (compared to $21.5 million a year earlier), but holds $276.6 million in cash, enough to last until 2028. Clinical data for all 12 patients with 12-month follow-up is expected any day now (Q2 2026), and dosing completion in REVEAL and ASPIRE is also this quarter.
\[Who Wins and Who Loses]
Winners:
- Taysha Gene Therapies (NASDAQ: TSHA). The company's stock has risen from $1.85 to $6.64 in recent months, analysts are unanimous in a "strong buy" rating, with an average target of $11.57. The FDA has essentially given a "green light" for accelerated approval based on 6-month data. This is every CEO's dream. For the company, Lucia is an operational risk that has been successfully "closed" by the protocol change.
- Sean Nolan (CEO Taysha). His team has done brilliant regulatory work. The Breakthrough Therapy Type B meeting with the FDA "confirmed alignment on the path to BLA." This is top-tier management.
- Children who will get into ASPIRE. Three families will gain access to therapy costing about $1 million per patient at the company's expense.
Losers:
- The Vaccaro family and dozens of families in similar situations. They are now trying to get through Health Canada's Special Access Program (SAP), but even with agency approval, Taysha is not obligated to provide the drug. And the price tag is at least $1 million, which the parents are trying to raise through crowdfunding. It's a lottery where the stake is a child's life.
- Health Canada and the Canadian system. Dr. Evdokia Anagnostou directly mentions "regulatory barriers" that make Canada unattractive for companies. While the FDA offers accelerated pathways, Canada remains on the sidelines of orphan innovation.
\[What the Media Isn't Saying]
And now — the main insider insight that no one is writing in the papers.
The problem: the protocol was changed not by the FDA, but by Taysha itself under FDA pressure, but these are not the same thing.
The wording in the company's statement — "based on robust historical data, scientific assessment, feedback, and alignment with the FDA" — is a classic euphemism. What actually happened? The FDA likely said: "We will not approve a broad label for all children aged 2 and older without additional data on the youngest group, because the risks of AAV9 therapy (dorsal root ganglion inflammation, hepatotoxicity, immune response) are different for a 2-year-old and a 5-year-old."
Insider insight: Age 4–5 is a "gray zone" of risk for intrathecal AAV9 administration. On one hand, the child is no longer an infant with a plastic immune system; on the other, not yet a teenager with adult cerebrospinal fluid volume. Taysha simply chose a cost-effective solution: enroll a group of 2–4, where safety is easier to prove (small patients with high needs), and a group of 6–22, where efficacy is easier to prove (measurable developmental milestones). Age 5 fell into the gap between the two cohorts. And the FDA was fine with it because the protocol became "cleaner" for statistics.
A second point that goes unmentioned: "the vial in the refrigerator" is a beautiful metaphor, but not reality.
Parents say: "We know that a vial of the drug is sitting in someone's refrigerator." This is emotionally understandable, but technically naive. Is TSHA-102 therapy produced for a specific patient? Largely, yes. Each dose is calibrated to cerebrospinal fluid volume and body weight. You can't just take a "vial" and inject it into Lucia — it would be a different dose, a different risk. The company cannot ethically deviate from the protocol approved by the Institutional Review Board (IRB). If they make an exception for Lucia, the protocol collapses, and the FDA may withdraw its alignment.
\[Forecast: Next 30 Days and 90 Days]
Next 30 days (end of June 2026):
The most volatile period. Long-term data for 12 patients from Part A of REVEAL with at least 12 months of follow-up is expected. If the data is good (and early signals — 83% response at 6 months, 100% at 9 months — are impressive), Taysha's stock could surge to $10-11. But for the Vaccaro family, this would mean time is definitively running out — the company will focus on filing the BLA, not on protocol exceptions.
Next 90 days (end of August 2026):
By then, dosing in ASPIRE (three children aged 2–4) will be complete. Taysha will announce "enrollment completion." Lucia's story will either be forgotten or become a precedent for Canada's Special Access Program. I predict that Health Canada may grant a "symbolic" access authorization, but Taysha will refuse to provide the drug outside the protocol, citing "resource prioritization for the final stage of clinical trials." This will spark a wave of criticism on social media and possibly even a parliamentary inquiry in Canada, but it won't change the regulatory reality.
Forecast: Lucia Vaccaro's story is not a bug but a feature of the orphan system. Until we create mechanisms for compassionate use at the level of mandatory quotas in every clinical protocol, such children will remain left behind. Taysha is right from its perspective: their duty to shareholders is BLA approval. But the moral price of that approval is exactly one five-year-old girl from Ottawa. And the industry has yet to figure out how to account for that on the balance sheet.
— Editorial Team
